Seller record · joinamble.com

Amble

Recorded September 2026 · Standard v1.1

Fails 2 of 8 criteria. S3, pharmacy identification: Nine pages were read, covering the terms, questions, safety, refund and privacy surfaces, and every reference is to a pharmacy network provider with no facility named. 1 more criterion also fails; see the table below.

Telehealth service. Passes 6 of 8 criteria. Recorded against Standard v1.1.

A telehealth service selling compounded GLP-1 drugs alongside NAD+, sermorelin, glutathione and lipotropic injections. Its plan table prints three monthly rungs, and a fourth figure sits in the page markup where no reader can see it.

Operating entity Amble Health, Inc.

Dispositions

Code	Criterion	Disposition	Where it was read
S1	Prescriber requirement	PASS	joinamble.com/faq
S2	Prescription gating	PASS	enroll.joinamble.com/start-online-visit/glp-nad-new
S3	Pharmacy identification	FAIL	joinamble.com/terms-of-service
S4	Compounding disclosure	PASS	joinamble.com/glp-1-injections
S5	Analytical documentation	FAIL	joinamble.com/faq
S6	Business address	PASS	joinamble.com/terms-of-service
S7	Price disclosure	PASS	joinamble.com/glp-1-injections
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

What was read, where, and on what date, for each disposition in the table above.

S1PASSThe questions page states that a state-licensed physician reviews the questionnaire, completes a clinical evaluation and, where state law requires, holds a live consultation.Source: joinamble.com/faq.

S2PASSThe order path was walked to an enrollment intake asking the weight-loss goal, reached before any product page and before any payment field.Source: enroll.joinamble.com/start-online-visit/glp-nad-new.

S3FAILNine pages were read, covering the terms, questions, safety, refund and privacy surfaces, and every reference is to a pharmacy network provider with no facility named.Source: joinamble.com/terms-of-service.

S4PASSThe GLP-1 product page states that compounded drugs are not Food and Drug Administration approved and do not undergo clinical studies for safety and efficacy.Source: joinamble.com/glp-1-injections.

S5FAILNine pages were searched for thirteen certificate and testing terms, and none returns a certificate, a lot number or a purity figure.Source: joinamble.com/faq.

S6PASSThe terms print two street addresses, a Madison Avenue suite in New York and a Warren Road address in Cortland, Ohio, the second of which is given for written notice.Source: joinamble.com/terms-of-service.

S7PASSThe rendered GLP-1 page prints three rungs at the same price for any dose: 179 dollars for one month, 160 dollars for three months and 135 dollars for six months. A fourth figure sits in the page markup inside a container set to display none, which no control on the page reveals, so it is not a published price and is not recorded as one.Source: joinamble.com/glp-1-injections.

S8PASSNo letter names the entity in the FDA index, and no action has halted the business; control letter found in the same run.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide, NAD+, sermorelin, glutathione, lipotropic injections.

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.